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Abstract
GEOGRAPHIC DISTRIBUTION OF THE RADIATION ONCOLOGY WORKFORCE:
IMPLICATIONS ON PROSTATE CANCER.
Sanjay Aneja and James B. Yu, Department of Therapeutic Radiology, Yale School of
Medicine, New Haven, CT
Previous analyses of the radiation oncology (RO) workforce have focused on gross numbers
and not geographic distribution. We investigated trends in the geographic distribution of the
radiation oncology workforce across the United States. Additionally, we assessed the impact
of geographic variations in the RO workforce on prostate cancer management and outcomes.
We hypothesized that geographic variations in the workforce would be associated with
prostate cancer management and prostate-cancer mortality.
We used the Area Resource File to calculate and map the ratio of radiation oncologists to the
population aged 65 or older (ROR) within different health service areas (HSA) across the
United States from 1995-2007. Multivariate regression models were built to test the
association between ROR and socioeconomic variables (income, minority population,
unemployment rate, population education). Using patient data from the Surveillance
Epidemiology End Results Program (SEER) we built multivariate logistic regression models
to test associations between variations in the RO workforce and patient decisions to observe,
undergo a radical prostatectomy, or undergo radiation therapy. Using mortality data from the
State Cancer Profiles dataset, we built multivariate linear regression to test the association
between RO workforce and count-level age-adjusted prostate cancer mortality.
Despite a 24% increase in the workforce from 1995 to 2007, there remained consistent
geographic maldistribution of radiation oncologists, specifically affecting the rural HSAs.
Regression analysis found higher ROR associated with more educated (p=.001), affluent
(p<.001) HSAs with lower unemployment rates (p<.001), and higher minority populations
(p=.022). Of the 108,612 prostate cancer patients queried from the SEER dataset, patients
with low-risk disease (p<.001) residing in HSAs with fewer radiation oncologists (p=.001.041), fewer urologists (p<.001), and more primary care physicians (p<.001) were most
likely to observed in lieu of curative treatment. Of the 91,643 patients who underwent some
form of curative treatment, older, single (p<.001), African American patients (p<.001) with
low-risk disease (p<.001) residing in HSAs with more radiation oncologists (p=.007-.001)
and primary care physicians (p<.001) were more likely to receive radiation therapy. The
presence of at least one radiation oncologist was associated with between 5.74% and 1.48%
reduction in prostate cancer mortality (p=.001-.045) even when adjusting for county-level
prostate cancer incidence.
Despite a modest growth in the radiation oncology workforce, there exists persistent
geographic maldistribution of radiation oncologists allocated along socioeconomic and racial
lines. Regional variations in the RO workforce are associated with variations in the
management of prostate cancer. The presence of at least one radiation oncologist is
associated with a reduction in county-level prostate cancer mortality. There is a need for
geographically aware policy in order to optimize the RO workforce and improve prostate
cancer outcomes.
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Introduction
The Physician Workforce Crisis
The physician workforce remains the cornerstone to delivering quality healthcare
across the United States. Over the last 30 years, population growth has rapidly outpaced
commensurate gains in the physician workforce threatening the sustainability of our
country’s healthcare system.1 With recent passage of the Patient Protection and
Affordable Care Act (ACA), the number of insured Americans is expected to increase by
32 million widening the physician supply gap and increasing the clinical burden on the
workforce.2 The Center for Workforce Studies projects the gap in the physician
workforce to increase by 50% by the year 2050. Specifically, the shortage of specialists is
expected to quadruple. 3 Because of this known association between access to care and
healthcare quality, the ACA attempted to address the physician workforce issue through
the establishment of the National Healthcare Workforce Commission, whose sole
purpose is to monitor the supply and distribution of physicians. Along with the National
Healthcare Workforce Commission, the ACA also established the Center for Medicare
and Medicaid Innovation Center whose mission is to optimize the efficiency and quality
of care provided by the current physician workforce.1
Geography and the Physician Workforce
Despite significant focus on the physician workforce problem, the geographic
distribution of the workforce is often overlooked. Previous policy analyses of the
physician workforce have primarily focused upon projecting future demand based on
gross numbers of physicians.4,5 Geographic variations on the workforce have been
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associated with disparities in health outcomes. Specifically within oncology, geographic
access to care has known associations with cancer-related outcomes. Increased urologist
density has been shown to be associated with decreased prostate and kidney cancer
mortality.6,7 Dermatologist density has been shown to be associated with reductions in
melanoma mortality.8 Additionally increased density of primary care physicians has been
associated with improved cancer specific mortality and all cause mortality.9 Moreover,
geographic proximity to cancer specialists has been associated with variations in the
management of breast cancer including surgical choice, and receipt of radiation
therapy.10-13 Whether the current physician workforce is adequately and equitably
distributed, to meet and optimize the growing demand for cancer care is an important
area of ongoing study.6,14-16
The Radiation Oncologist Workforce
The workforce issue is not new to the field of radiation oncology. In 2002 the
American Society for Radiology Oncology (ASTRO) Workforce Committee was the first
to note shortages in the future of radiation oncology.17 More recently however, it has
been projected that the demand for radiation therapy will increase 10 times faster than the
supply for radiation oncologists.18 The radiation oncology workforce problem has likely
exacerbated since ASTRO’s first report for at least three reasons. First, technological
advancements in the field of radiation oncology have markedly increased the overall
demand of radiation therapy to treat cancer despite recent declines in cancer
incidence.18,19 Second, a supply gap has been created by modest increases in the number
of training programs in the face of larger increases clinical demands.18,20 Third,
technological advancements in the field that not only increased the quantity of treatment
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but also physician planning time have potentially decreased the overall efficiency of the
radiation oncologist workforce.18,21
Similar to other specialties, previous analyses of the radiation oncology workforce
have focused solely on radiation oncologist numbers and projecting the need for the
future. Few studies, however, have addressed the geographic distribution of radiation
oncologists. Though some disciplines may adapt to a lack of geographic distribution via
the use of telemedicine or physician extenders, access to radiation oncology services is
particularly dependent on geographic distribution for several reasons. First, a clinical
course of radiation therapy requires multiple daily trips for treatment, for up to eight or
nine weeks in some cases. Second, given the technical nature of radiation oncology,
primary care physicians and physician extenders cannot as readily fill gaps in care caused
by lack of radiation oncologists. Third, radiation therapy requires large and immobile
equipment that cannot feasibly be transported or quickly erected.22 Descriptive analysis
of the geographic distribution of the radiation oncology workforce is a necessary first
step to help inform policy makers and clinicians in ways to best provide radiation therapy
and multidisciplinary cancer care.
Treatment of Prostate Cancer across the United States
Prostate cancer is the most common non-cutaneous cancer among men in the
Western world. With an estimated 200,000 diagnoses and 30,000 deaths each year,
treatment of prostate cancer is of great medical and public significance.23 24 Despite its
high occurrence rate, the relative 10-year survival rate following treatment of localized
prostate cancer is 98%.23 Though evidence indicates that prostate cancer mortality has
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been improving in recent years, the benefit from modern cancer treatment may not be
uniform throughout the United States.25,26 Furthermore, as US population ages, the
incidence of prostate cancer is expected to increase dramatically over the next 20 years.
In addition to active surveillance, the two most common treatment interventions for
patients with localized prostate cancer are prostatectomy and radiation therapy. Although
no multi-institutional randomized control trials have compared the two modalities,
retrospective studies from the Cleveland Clinic, Memorial Sloan Kettering Cancer Center,
and the Joint Center for Radiation Therapy have all found similar biochemical failure
rates among both modalities. 27-29 Moreover, despite the different side-effects profiles for
each treatment option, recent evidence has found no significant differences in 15-year
disease specific functional outcomes when comparing radical prostatectomy and external
beam radiation therapy.30
Several types of providers are involved in the diagnosis and treatment of prostate
cancer. Primary care providers and urologists are typically involved in initial diagnosis
whereas urologists, medical oncologists, and radiation oncologists could all potentially be
involved in the primary treatment of prostate cancer. Patients are often influenced by
counseling physicians when deciding their optimal treatment choice.31 This is particularly
concerning given physicians opinions regarding both treatment modalities vary
drastically based on specialty and geographic region.31 The influence the distribution of
radiation oncologists, urologist and primary care providers on the management of
prostate cancer remains unclear.
Furthermore, the relative impact of the distribution of radiation oncologists,
urologists, and primary care providers on prostate cancer mortality is unknown. As
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radiation oncologists also serve as primary treatment providers for prostate cancer, the
association between the availability of radiation oncologists and prostate cancer mortality
merits exploration.
It is likely that variation in the geographic distribution of radiation oncologists is
related to the receipt of cancer treatment and outcomes, particularly for those patients
who are not candidates for surgery. Alternatively, patients who are surgical candidates,
but refuse surgery, may choose radiation therapy as an alternative curative treatment if a
radiation oncologist is geographically accessible. External beam radiotherapy, the
dominant form of radiation treatment in the US, typically requires multiple daily
radiation treatments for 6-9 weeks, making the geographic distribution of radiation
oncologists more important, particularly for patients with limited mobility and resources
for travel. As it is known that travel time to the nearest cancer center varies significantly
throughout the country, inequities in geographic access may be associated with variations
in cancer mortality.32
To investigate these issues, we studied trends in the geographic distribution of the
radiation oncology workforce across the United States. Additionally, we studied the
association between geographic variations in the radiation oncology workforce and
regional prostate cancer management and mortality. We hypothesized that there existed
geographic variations in the radiation oncology workforce that were associated with
differences in the treatment choices of prostate cancer patients as well as prostate cancer
mortality.
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Project Aims
1. To evaluation trends in the geographic distribution of the radiation oncology
workforce from 1995 to 2007.
2. To compare the trends in geographic distribution of the radiation oncology workforce
to the primary care physician and total physician workforces from 1995 to 2007.
3. To identify population and geographic factors associated with the distribution of the
radiation oncologists in 2007.
4. To evaluate associations between geographic variations in the radiation oncology
workforce and patient prostate cancer treatment choice from 2004 to 2007
5. To evaluate associations between geographic variations in the radiation oncology
workforce and regional prostate-cancer mortality rates from 2003 to 2007.
Hypothesis
We expect to find significant geographic variations in the radiation oncology workforce
that have persisted from 1995 to 2007. We also expect to find an association between
regional variations in the radiation oncology workforce and the management of prostate
cancer. Specifically, we expect regions with higher densities of radiation oncologists to
have lower rates of surveillance and higher rates of radiation therapy treatment. Finally,
we expect regions with higher densities of radiation oncologists to be associated with
lower prostate cancer mortality rates.
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Methods
Data Sources
This study utilized three publically available data sources. The Area Resource File
provided regional demographic, population, and physician distribution data.33,34 The
Surveillance Epidemiology End Results Public-Use Dataset provided clinical,
demographic, and treatment data for patients diagnosed with prostate cancer. 34 Finally,
the State Cancer Profiles Dataset provided regional prostate cancer specific mortality
data.35
The Area Resource File
Using the 1995 and 2007 editions of the Area Resource File (ARF), we obtained
demographic, population, and physician distribution data.33 Published by the Health
Resources and Services Administration of the US Department of Health and Human
Services, the ARF is a collection of data from over 50 sources, including the American
Medical Association, American Hospitalization Association, US Census, and National
Center for US Health Statistics. The ARF aggregates information concerning the
healthcare professionals, healthcare facilities, and population for each county in the
United States. Specifically, the ARF includes the number of specialists within each
county based on data from the American Medical Association (AMA) Physician
Masterfile.
The Surveillance Epidemiology End Results Public-Use Dataset
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We obtained patient linked prostate cancer treatment choice data from the
Surveillance Epidemiology End Results (SEER) Public-Use Dataset. The SEER PublicUse Dataset provided demographic staging, pathologic findings, extent of surgery, and
receipt of radiation therapy for patients treated with prostate cancer for the years 2004
through 2007. Originally established in 1973 by the National Cancer Institute (NCI) the
SEER Public-Use Dataset is an aggregate of population-based cancer registries across the
United States. The SEER Public-Use Dataset comprises approximately 26% of the United
States. The following state and individual population-based registries were included our
analysis: Alaska Native Tumor Registry, Arizona Indians, Cherokee Nation, Connecticut,
Detroit, Georgia Center for Cancer Statistics, Atlanta, Greater Georgia, Rural Georgia,
Greater Bay Area Cancer Registry, San Francisco-Oakland, San Jose-Monterey, Greater
California, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico,
Seattle-Puget Sound, Utah.34,36
The State Cancer Profiles Dataset
County level prostate cancer specific mortality and incidence data was obtained
from the State Cancer Profiles Dataset. The State Cancer Profiles Dataset is a merged
dataset from the NCI SEER program, National Program for Cancer Registries (NPCR),
and United States Center for Disease Control and Prevention’s National Vital Statistics
System.35 Prostate cancer specific mortality and incidence data were reported as ageadjusted average rates per 100,000 people from the years 2003 to 2007. Cancer
incidences and mortalities were assigned to counties based on patient residence at the
time of diagnosis and death, respectively.
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Geographic Units of Analysis
National Cancer Institute Health Service Areas
When evaluating trends in the geographic distribution of the radiation oncology
workforce and the influence of geographic variations on prostate cancer treatment choice
the geographic units of analysis were the 950 Health Service Areas (HSAs) within the
United States as defined by the National Cancer Institute. HSAs are defined as a single
county or group of contiguous counties that remain self-contained with respect to hospital
care.16 HSAs were chosen as the unit of analysis because they best represent geographic
access to healthcare within a region. County level data from the ARF was aggregated to
HSAs using simple summation for physician and population variables and population
weighted sums descriptive variables. Patients within the SEER Public-Use Dataset were
assigned HSAs based on county-specific FIPS codes assigned to the patient based on
residence. The data from the SEER Public-Use Dataset contained data for patients
located in 170 HSAs comprising approximately 17.9% of the United States.
United States Counties
When evaluating the association between geographic variations in the radiation
oncology workforce and regional prostate cancer specific mortality the geographic units
of analysis were the 3,141 counties in the United States as defined by the 2000 Census.
Counties were specifically chosen for analysis of regional prostate cancer specific
mortality because the State Cancer Profiles dataset that could not be accurately
aggregated to HSAs. Similar to previous studies investigating the impact of physician
density on cancer-related mortality, rural counties were excluded from the analysis
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because only 0.4% of the 669 rural counties in the United States possessed radiation
oncologists and many of them lacked complete mortality data.6,8 Following exclusion of
rural counties, 2,472 non-rural counties comprising approximately 78.7% of the United
States possessed complete mortality data and were available for analysis. Counties were
classified as rural based on 2003 Department of Agriculture Rural/Urban Continuum
Codes.
Trends in the Geographic Distribution of the Radiation Oncology Workforce
To evaluate the geographic distribution of radiation oncologists across the United
States the primary outcome was the ratio of radiation oncologists to population aged 65
or older (ROR). The physician to population ratio remains a frequently used measure of
physician distribution within a region. 6,37 The elderly were chosen as the population of
interest because they represent a group that has the highest prevalence of cancer and
represent a demographic which utilizes a significant portion of healthcare services in the
United States. 18,38 In addition, elderly patients may be less mobile than younger patients,
and may be more hesitant to travel long distances for their care meaning geographic
proximity is of utmost importance. The ROR of each HSA was calculated as the number
of radiation oncologists per 100,000 people aged 65 or older. RORs for each HSA were
generated for the years 1995 and 2007. To compare the distribution of radiation
oncologists to other physician specialties, equivalent ratios were calculated for the
primary care physician (PCPR) and total physician (MDR) workforces. PCPs were
defined as physicians in general practice, family practice, or general internal medicine.
Population aged 65 or older estimates and physician workforce estimates were obtained
from the ARF.
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To evaluate changes in the distribution of the workforce, mean RORs were
calculated for 1995 and 2007 and compared with equivalent changes in PCPR and MDR.
To assess the current distribution of radiation oncologists, each HSA was ranked based
on ROR and compared to equivalent rankings of PCPRs and MDRs. In an effort to
visually compare the distribution of radiation oncologists between different HSAs and
trends in their distribution, ROR values were mapped to corresponding HSAs.
Lorenz Curves and Gini Coefficients
Traditionally used to assess distribution of wealth, Gini coefficients and Lorenz
curves have recently been used to evaluate physician distribution. 37,39,40 The Lorenz
curve was constructed by graphing the cumulative percentage of radiation oncologists as
ranked by RORs versus the cumulative percentage of the population age 65 or older. A
45° line representing a perfectly even distribution was drawn from the origin to the
maximum point of the Lorenz curve. The Gini coefficient was calculated by dividing the
area between the Lorenz curve and the 45° line by the total area under the 45° line. The
Gini coefficient ranges in value from 0 (complete equity) to 1 (complete inequity) and
serves as a quantitative way to describe relative ‘evenness’ of physician distribution.
Because Gini coefficients possess a linear relationship, changes in value can be used to
evaluate changes in the evenness of physician distributions over time. Lorenz curves and
Gini coefficients were generated to examine the radiation oncologist distribution among
all HSAs between 1995 and 2007. Subgroup analysis was performed to compare the
evenness of radiation oncologist distribution, specifically in less populated HSAs, using
population quartiles. To assess the uniqueness of the radiation oncologist distribution
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compared to all other physicians and PCPs, Lorenz curves and Gini coefficients were also
calculated for all physicians and PCPs between 1995 and 2007.
Negative Binomial Regression Analysis
To evaluate population characteristics potentially associated with the current
geographic distribution of radiation oncologists, regression analysis was used. After
assessing distribution, mean, and variance of HSA-level ROR, zero-inflated negative
binomial regression was chosen. The dependent variable was ROR for the year 2007. The
independent variables included county level population race, income, education, and
unemployment rate obtained from the ARF that were aggregated to HSA level using
weighted sums. Population race was defined as percentage white population within each
HSA from the 2000 Census. Population income was defined as the median household
income according to the 2007 Census update. Population education was defined as
percentage population age 25 or older with at least a high school education according to
the 2000 Census. Finally, unemployment rates for each HSA were from the 2007 Bureau
of Labor Statistics estimates. Independent multivariate regression models were built
using backwards-stepwise selection with a univariate p<.15 for inclusion into the model.
A Vuong test was used to assess the appropriateness of the model. Statistical significance
was determined at p<.05.
Radiation Oncologist Distribution and Prostate Cancer Management
To evaluate whether variations in the distribution of radiation oncologists was
associated patient decisions to undergo treatment for prostate cancer, prostate cancer
treatment and patient data were obtained from the SEER Public-Use dataset and merged
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with physician workforce and socioeconomic data from the ARF for the years 2004
through 2007. Each prostate cancer patient within the registry was assigned physician
workforce densities and socioeconomic data based on their HSA of residence. In addition
to radiation oncologist densities, primary care physician and urologist densities were also
obtained because of their previously described influence on prostate cancer screening and
treatment outcomes.6,31 Densities were reported per 100,000 residents using 4-year (20042007) population averages based on US Census estimates. To examine if incremental
changes in radiation oncologist density accompany changes in the management of
prostate cancer, radiation oncologist densities were categorized (0, 0.1 to 1.0, 1.1 to 2, 2.1
to 3.0, >3.0 per 100,000 people). Socioeconomic variables of interest included
population income, unemployment rates, and population education. The socioeconomic
data were obtained from the ARF and aggregated as stated above.
Because appropriate prostate cancer intervention varies based on aggressiveness
of disease patients were classified into low, intermediate and high-risk categories based
on NCCN criteria.41 Patients were defined as ‘low-risk’ if their prostate cancer was
Gleason 6, possessed a PSA < 10.0, and staged T1cN0M0. Patients were defined as
‘high-risk’ if their prostate cancer was Gleason 8-10, presented with a PSA > 20.0, or
staged T3N0M0. Individual patient characteristics were obtained from the SEER-Public
Use data and included in the analysis. Patient characteristics of interest were patient race,
age, and marital status. Treatment choice data obtained from the SEER Public-Use
Dataset and were defined as ‘observation’ or ‘attempted curative therapy’. Attempted
curative therapy consisted of a radical prostatectomy, radiation therapy (External-Beam
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Radiation Therapy and brachytherapy) or combination surgical and radiation therapy
treatment.
Logistic Regression Analysis
A primary logistic regression model was built for the entire cohort to evaluate the
association between radiation oncologist density and observation of prostate cancer. For
patients who attempted curative therapy, two additional logistic models were built to test
the association between radiation oncologist densities and the type of curative therapy
chosen. The primary outcome variables for these additional models were receipt of a
radical prostatectomy and receipt of radiation therapy respectively. Independent
multivariate regression models using the above covariates were built using backwardsstepwise selection with a univariate p<.15 for inclusion into the multivariate model.
Statistical significance was determined at p<.05.
Radiation Oncologist Distribution and Prostate Cancer Mortality
To evaluate whether regional variations in the radiation oncologist workforce
impacted prostate cancer outcomes, physician workforce and socioeconomic data from
the ARF was combined with county-level prostate cancer specific mortality data from the
State Cancer Profiles Dataset for the years 2003 through 2007. Socioeconomic variables
of interest included population income, unemployment rates, and population education as
defined above. To account for geographic variations patient populations, percent
population Caucasian, percent population aged 65 or older based on the Census County
File were also included in the analysis.
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In addition to radiation oncologist density, urologist and primary care physician
densities were analyzed. In an effort to assess if reductions in prostate cancer mortality
were related to non-specific specialists, a non-oncology specialty, Allergy-Immunology,
was chosen as a control variable to test whether changes in cancer mortality were more
specifically attributed to radiation oncologist density. Allergists-Immunologists were
chosen a priori as an ideal comparison specialist because they have no known
associations to prostate cancer management and possess a workforce size and geographic
distribution similar to that of radiation oncology. Physician densities were calculated as
five-year means (2003 to 2007) of physicians per 100,000 people using annual Census
county population estimates.
Prostate cancer specific mortality data from the State Cancer Profiles data were
reported as county-level age-adjusted average rates per 100,000 people from the years
2003 to 2007. In an effort to better examine if incremental changes in radiation
oncologist density accompany changes in prostate cancer mortality, radiation oncologist
densities were categorized (0, 0.1 to 1.0, 1.1 to 2, 2.1 to 4.0, >4.0 per 100,000 people). To
account for potential geographic variations in prostate cancer screening, prostate cancer
incidence among counties in the United States was also included in the model. Cancer
incidences and mortalities were calculated for each county based on each a patient’s
residence at the time of diagnosis and death, respectively.
Linear Regression Analysis
A linear regression model was built with prostate cancer mortality per 100,000
people as the primary outcome variable. Univariate associations between physician

	
  

20	
  

workforce, health system, and socioeconomic predictor variables and cancer mortality
were calculated using t tests for categorical variables and linear regression for continuous
variables. The multivariate model were built using backward stepwise selection with a
univariate p<0.15 for inclusion into the model. Allergist-Immunologist density was
manually inserted into the final model to control for changes in cancer mortality that
could potentially be attributed to a high overall specialist density. Statistically
insignificant Allergist-Immunologist density in the final model would suggest changes in
cancer mortality were likely unattributed to high overall specialist density. Statistical
significance for the final models was determined at p<0.05. Variance inflation factors
were used to control for excessive collinearity amongst variables. Percent changes in
mortality were calculated for each density category using the cancer mortality of a
reference group. The reference group in all three models was a county with no radiation
oncologists, urologists or allergists. To evaluate incremental benefits derived from
increasing radiation oncologist density beyond the reference group, linear combination
estimates were calculated comparing radiation oncologists among different density
categories.
Statistical analysis was conducted using SAS Version 9.2 (SAS, Cary, NC) and
Stata Version 9.2 (Stata, College Station, TX). Mapping of data was done using the
geographical information system ArcGIS Version 9.2 (Environmental Systems Research
Institute, Inc., Redlands, CA). Transformation of data between geographic units was done
using a combination of ArcGIS Version 9.2 (Environmental Systems Research Institute,
Inc., Redlands, CA), SAS Version 9.2 (SAS, Cary, NC) and Stata Version 9.2 (Stata,
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College Station, TX). All data transformation, statistical analysis, and map creation was
completed independently by Sanjay Aneja, BS and overseen by James B. Yu, MD.
Results
Trends in the Geographic Distribution of the Radiation Oncology Workforce
In the twelve-year period of our study, the radiation oncology workforce grew
approximately 24%, from 3,515 radiation oncologists in 1995 to 4,378 in 2007. Over the
same time period, the PCP workforce grew approximately 31%, from 213,619 physicians
to 278,728. Similarly, the overall physician workforce grew 29%, from 617,362
physicians to 794,184. The mean ROR increased by slightly more than one radiation
oncologist per 100,000 people. (Table 1) In contrast, mean PCPR and MDR increased by
85 physicians per 100,000 people and 145 physicians per 100,000 people, respectively.
Increases in the mean ROR, although modest, suggest a growth in the radiation oncology
workforce that outpaced the growth of the elderly population.
Table 1: Mean Physician to Population Aged 65 or Older Ratio: 1995 and 2007
1995

2007

% Change

Radiation Oncologists per 100,000

5.08

6.16

21.26

PCP per 100,000

521.67

606.50

16.26

MD per 100,000

1056.44

1201.35

13.72

The distribution of radiation oncologists was significantly more skewed than
PCPs and MDs. In the year 2007, approximately 44% of HSAs within the United States
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lacked a radiation oncologist. Comparatively, approximately .74% of HSAs lacked a PCP
and .63% lacked a physician of any kind. Moreover, approximately 75% of HSAs had
two or fewer radiation oncologists per 100,000 people aged 65 or older. Additionally,
there existed consistent geographic maldistribution of radiation oncologists from 1995 to
2007. (Figure 1) HSAs within the Northeast, California, and Florida exhibited high
RORs in both 1995 and 2007, whereas rural HSAs within the Midwest generally
exhibited lower RORs in 1995 and 2007 relative to the rest of the country. (Figure 2)
Figure 1: Distribution of Radiation Oncologists Among Health Service Areas: 1995, 2007
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Figure 2: Ratios of Radiation Oncologists to Population Aged 65 or Older Among Health
Service Areas: 1995, 2007

Equitable Distribution of the Radiation Oncologist Workforce
Gini coefficient calculations confirmed the maldistribution of the radiation
oncology workforce. Radiation oncologists were less evenly distributed than both PCPs
and MDs in both 1995 and 2007. (Table 2) However, the Gini coefficients of all three
groups exhibited a percentage decrease, indicating an improvement in distribution
towards equity. Radiation oncologists exhibited the largest change (-10.93%), followed
by PCPs (-4.85%) and finally MDs (-2.34%). Analysis of Gini coefficients within
population quartiles highlighted the uneven distribution of radiation oncologists in nonmetropolitan areas. Specifically we found that, unlike PCPs and MDs who possessed
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relatively similar Gini coefficients among different population quartiles, the Gini
coefficient of radiation oncologists in the lowest population quartile was an
inequitable .951, compared to .251 in the highest population quartile. (Table 3) The
difference between Gini coefficients among population quartiles suggests the geographic
maldistribution of radiation oncologists stems primarily from inequity in less populated
non-metropolitan HSAs.
Table 2: Trends Gini Coefficients Among Different Physicians, 1995-2007
1995

2007

Change

% Change

Radiation Oncologists

0.366

0.326

-0.040

-10.93

PCP

0.206

0.196

-0.010

-4.85

MD

0.299

0.292

-0.007

-2.34

Table 3: Gini Coefficients Among Population Quartiles, 2007
Quartile 1

Quartile 2

Quartile 3

Quartile 4

Radiation Oncologists

0.951

0.675

0.402

0.251

PCP

0.268

0.233

0.232

0.169

MD

0.333

0.258

0.265

0.236

Factors Associated with Radiation Oncologist Distribution
Regression analysis found an association between radiation oncologist
distribution and population characteristics. Univariate Zero Inflated Negative Binomial
Regression showed that increased ROR in 2007 was associated with HSAs with lower
unemployment rates (p<.001), higher household incomes (p<.001), and higher education
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rates (p=.001). (Table 4) Surprisingly, decreased ROR in 2007 was associated with
HSAs that had higher percent white population (p=.022). Multivariate analysis confirmed
the association between increased ROR and lower unemployment rates (p<.001), higher
household incomes (p<.001), and increased minority population (p=.010). Higher
education rates proved to be insignificant in the multivariate model (p= .461). Because
the association between minority population and ROR was unexpected, a separate model
using percent African American population was built to confirm the association with
minority groups. The confirmatory model yielded similar results (p<.001).
Table 4: Socioeconomic Factors Associated with ROR: 2007
Univariate

Multivariate

Independent
Variable

Incidence
Rate
Ratio

Incidence
Rate
Ratio

p

p

Percent White
Population

.995

.022

.992

.999

.995

.010

.991

.978

Unemployment
Rate

.889

<.001

.858

.921

.906

<.001

.872

.891

Percent High
School
Education

1.01

.001

1.00

1.02

1.01

.461

.999

1.02

Median
Household
Income (in
$10K)

1.01

<.001

1.00

1.02

1.01

<.001

1.00

1.02

95% CI

95% CI

Radiation Oncologist Distribution and Prostate Cancer Management
We isolated 108,613 prostate cancer patients from the SEER Public-Use Dataset.
16,969 (15.6%) patients opted for active surveillance of their prostate cancer. (Table 5)
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47,484 (43.7%) of patients underwent some form of radiation therapy and 45,367
(41,8%) underwent radical prostatectomy. Single (p<.001), older (p<.001), African
American (p<.001) patients with low-risk disease (p<.001) residing in HSAs with fewer
radiation oncologists (p=.001-.041), fewer urologists (p<.001), and more primary care
physicians (p<.001) were most likely to pursue active surveillance. (Table 6) Of the
91,643 (84.38%) of patients who underwent some form of curative treatment, older,
single (p<.001), African American patients (p<.001) with low-risk disease (p<.001)
residing in HSAs with more radiation oncologists (p=.007-.001) and primary care
physicians (p<.001) were more likely to some form of receive radiation therapy. (Table
7) Conversely, married (p<.001), white (p<.001), younger (p<.001) patients with higher
risk disease (p<.001) living in HSAs with fewer radiation oncologists (p=.006-.001),
more urologists (p<.001) and fewer primary care physicians (p<.001) were likely to
receive a radical prostatectomy. Incremental increases in radiation oncologist density
were associated with commiserate decreases likelihood of surgical treatment and
observation.
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Table 5: Prostate Cancer Patients: SEER Public-Use Dataset 2004-2007

Total
Treatment Choice
Observation
Radiation Therapy
Radical Prostatectomy
Race
White
African American
Other
Married
NCCN Risk Group
Low Risk
Intermediate Risk
High Risk

N
108,613

%
100.0%

16,969
47,484
45,367

15.6%
43.7%
41.8%

88,898
13,586
6,058
85,106

81.8%
12.5%
5.6%
78.4%

30,782
61,863

28.3%
57.0%

15,967

14.7%

Median

	
  

Age
Radiation Oncologists
Per 100,000
Urologists Per 100,000

65
1.44
3.29

PCP Per 100,000

66.69
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Table 6: Predictors of Active Surveillance of Prostate Cancer: 2004 to 2007

Observation

	
  

Odds
Ratio

P

95% CI

Radiation Oncologists
per 100,000
>0-1.0 v 0
>1.0-2.0 v 0
>2.0-3.0 v 0
>3.0 v 0
Urologists per
100,000
PCPs per 100,000
Age
Race
African American v
White
Other v White
Married
NCCN Risk Group
Intermediate v Low

.895
.856
.845
.851

.030
.001
.002
.041

.810
.847
.758
.730

.989
.864
.942
.994

.920
1.005
1.097

<.001
<.001
<.001

.902
1.004
1.094

.939
1.007
1.099

1.621
.878
0.632

<.001
.001
<.001

1.540
.814
0.608

1.706
.947
0.658

0.607

<.001

0.584

0.632

High v Low

0.765

<.001

0.726

0.806
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Table 7: Predictors of Prostate Cancer Treatment Interventions: 2004 to 2007

Radiation
Oncologists
per 100,000
>0-1.0 v 0
>1.0-2.0 v 0
>2.0-3.0 v 0
>3.0 v 0
Urologists
per 100,000
PCPs per
100,000
Age
Race
African
American v
White
Other v
White
Married
NCCN Risk
Group
Intermediate
v Low
High v Low

Radical Prostatectomy
Odds
Ratio
P
95% CI

Odds
Ratio

Radiation Therapy
P

.886
.832
.814
.729

.006
<.001
<.001
<.001

0.813
0.825
0.741
0.638

.967
.839
.894
.833

1.125
1.194
1.261
1.370

.007
.001
<.001
<.001

1.033
1.062
1.149
1.201

1.226
1.326
1.383
1.563

1.129

<.001

1.084

1.173

0.985

.071

.968

1.001

.995
.877

<.001
<.001

0.994
0.875

.997
.879

1.005
1.125

<.001
<.001

1.004
1.123

1.006
1.128

.545

<.001

.520

.571

1.779

<.001

1.698

1.863

.912
1.517

.006
<.001

.854
1.461

.974
1.574

1.154
0.690

<.001
<.001

1.081
0.665

1.232
0.716

2.010

<.001

1.943

2.080

0.534

<.001

0.516

0.552

1.388

<.001

1.320

1.458

1.009

0.711

0.961

1.061

95% CI

Radiation Oncologist Distribution and Prostate Cancer Mortality
Similar to HSAs the radiation oncologist was heterogeneously distributed among
counties in the United States, with 1,616 (65.3%) counties lacking the presence of any
radiation oncologists. (Figure 3) Of the 2,472 counties studied 1205 (48.7%) were
without the presence of both a radiation oncologist and urologist. The mean radiation
oncology and urologist densities among counties were .65 and 2.00 per 100,000
respectively. The baseline prostate cancer mortality in a county without the presence of a
radiation oncologist, urologist, or allergist was 38.68 deaths per 100,000 people (95% CI
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33.94-43.42). The presence of a radiation oncologist was associated with a statistically
significant reduction in prostate cancer mortality, despite adjusting for variations in
urologist and allergist/immunologist density, as well as socioeconomic, demographic and
health system characteristics (Table 8). Compared to counties without radiation
oncologists, having >0-1, 1-2, or 2-4 radiation oncologists per 100,000 people
significantly reduced prostate cancer specific mortality by -3.65% (p=0.031), 5.74%
(p<0.001), and 1.48% (p=0.045), respectively. The prostate cancer specific mortality of
patients residing in a county with 4 or more radiation oncologists per 100,000 people was
not significantly different from counties where there were no radiation oncologists
(p=.769). The confidence intervals of this group were wide, given the small number of
counties with 4 or more radiation oncologists per 100,000 residents. (Figure 4) Linear
combination estimates found increasing radiation oncologist density beyond 1.0 per
100,000 provided no statistically significant incremental reductions in prostate cancer
mortality compared to having 0.1-1.0 radiation oncologists per 100,000. (Table 9)
Figure 3: Distributions of Radiation Oncologists and Urologists Among US Counties
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% Reduction in Prostate Cancer
Mortality

Figure 4: Reduction in Prostate Cancer Mortality for a Given Radiation Oncologist Density
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Table 8: Predictors of County Level Prostate Cancer Mortality: 2003-2007
% Change in
Prostate Cancer
Mortality

P

>0-1.0 v 0

-3.65

.031

-5.54

-1.76

>1.0-2.0 v 0

-5.74

<.001

-7.87

-3.61

>2.0-4.0 v 0

-1.48

.045

-2.73

-0.23

>4.0 v 0

-1.09

.769

-3.69

1.51

Urologists per 100,000 People

-12.63

<.001

-16.43

-6.60

Allergist Immunologists per
100,000 People

-0.59

.340

-1.80

0.62

Percent Population Aged 65 or
Older

1.23

.001

0.51

1.94

Median Household Income (in
$10,000)

-2.97

<.001

-4.17

-1.76

Percent Population with High
school Education

-0.17

<.001

-0.01

-5.14

Percent White Population

-0.39

<.001

-0.47

-0.31

Prostate Cancer Incidence

0.05

.007

0.01

0.09

95% CI

Radiation Oncologists per 100,000
People

Prostate cancer
deaths per
100,000 people
Reference Group: Prostate Cancer
Mortality in a county with no
radiation oncologists, urologists or
allergists

38.68

95% CI

33.94

43.42

*Note: Primary care physician density, and unemployment rate either did not meet univariate
inclusion criteria or were not statistically significant in multivariate model.
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Table 9: Incremental Benefit of Increasing Radiation Oncologist Density on Prostate
Cancer Mortality
Prostate Cancer Mortality
Radiation Oncology Density
Categories

% Change in Mortality

P

OR

1.1-2.0 v 0.1-1.0

-2.1

0.221

0.45

2.1-4.0 v 1.1-2.0

4.3

.190

1.81

>4.0 v 2.1-4.0

0.4

.912

1.16

Consistent with previous studies, increasing density of urologists also was
associated with a reduction in prostate cancer mortality (p<.001). Allergist/Immunologist
density was not related to prostate cancer mortality (p=0.340). Residing in a more
affluent county with a younger and more educated population was correlated with
reduced prostate cancer mortality (Table 8). Moreover, racial makeup of counties was
found to be associated with variations in prostate cancer mortality. Counties with higher
percentages of Caucasians were associated with reduction in prostate cancer mortality
(p<.001). Primary care physician density and county unemployment rate were both not
significant in the multivariate model.
Discussion
This study serves as one of the first comprehensive geographic analyses of the
radiation oncology workforce. We found that despite a modest growth in the radiation
oncology workforce over the 12 years there remained a persistent geographic
maldistribution of radiation oncologists across the United States. The uneven distribution
of radiation oncologists is associated with socioeconomic characteristics and most
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profoundly seen in rural regions. Moreover, the growth in the radiation oncology
workforce over the 12 years did not match the growth of the overall physician workforce
and primary care workforces during the same period of time. Furthermore, geographic
variations in the workforce were associated with regional variations in the management
of prostate cancer. Finally and arguably most concerning, we found an association
between geographic variations in the radiation oncologist workforce and county-level
prostate cancer outcomes with regions lacking radiation oncologists having increased
prostate cancer specific mortality rates even when adjusted for variations in prostate
cancer incidence. Our study suggests that the physician workforce problem should not
merely focus on physician numbers but also the geographic distribution of physicians.
The growth in the radiation oncology workforce was modest compared to the
overall growth in the physician workforce. The radiation oncology workforce grew 5%
less than the overall physician workforce and 9% less than the primary care workforce. In
a 12-year period, the mean ROR increased by slightly more than one radiation oncologist
per 100,000 people aged 65 or older compared to larger increases in the PCPR and MDRs.
The modest growth in the radiation oncology workforce is most likely due to increasing
residency positions for radiation oncology.42-44
Despite growth in the workforce, there was persistent geographic variation in the
distribution of radiation oncologists in 1995 and 2007. Mapping of the RORs for 1995
and 2007 showed large geographic segments of the elderly population having little or no
access to radiation therapy services, specifically in non-metropolitan areas. In 2007, an
alarming 44% of HSAs in the United States lacked radiation oncologists. This translated
to 3,137,580 people aged 65 or older without access to radiation therapy in their HSA.
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Comparatively, Gini analysis showed radiation oncologists were less evenly distributed
than both PCPs and the overall physician workforce. Our finding that PCPs were the
most evenly distributed replicates findings from previous studies and suggests that recent
policy initiatives to increase geographic access to primary care have been successful. 37,45
More interestingly, the main driver in the uneven geographic distribution of radiation
oncologists was an inequitable distribution in less populated non-metropolitan HSAs.
The lack of access to radiation oncologists in less populated non-metropolitan areas is
perhaps due to the large capital investment required to obtain the equipment and
resources necessary to establish a radiation oncology practice. These impediments are
increased in rural areas where patient population levels are potentially less. Conversely,
large pockets of radiation oncologists were centered in metropolitan areas with large
academic centers. This finding corroborates previous findings from the ASTRO
workforce committee that groups of ten or more radiation oncologists are more likely to
be in academic centers. 17 The clustering of radiation oncologists in academic centers is
perhaps due to recent increases in academic radiation oncology due to an influx of
physician scientists in radiation oncology residency programs, or due to the attractiveness
of technological resources available at academic centers.46
Our analysis found that access to radiation oncology services was allocated along
socioeconomic and racial characteristics and provides information for policy makers on
potential factors that affect radiation oncologist distribution, and could be used for future
legislation aimed at physician recruitment to underserved areas. Although Hayanga et al
found access to radiation oncologists to be associated with decreased minority population
on the county level, our analysis found a positive association between minority
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population and ROR within HSAs.47 The reason for this difference is partly because our
negative binomial regression model more accurately predicted radiation oncologist
density given the distribution compared to the linear regression used in their analysis.
Also, our geographic units of analysis were HSAs, which better predict patterns of
healthcare usage compared to counties. Additionally, unlike previous analysis, our ROR
outcome variable accounts for the variation in population density across the United States
and is more accurate than gross physician totals. Moreover, unlike previous analyses, our
analysis excluded counties located in US territories such as Guam, Puerto Rico and the
US Virgin Islands that generally have disproportionate minority populations and skewed
access to specialists. Our findings suggest that, although racial disparities in cancer
outcomes have been well documented, minority populations generally reside within
HSAs in close proximity to radiation oncologists. 48
Our findings highlight the problem of physician recruitment to rural areas.
Recently, rural physician recruitment efforts have faced obstacles because of the
technological gap that exists in rural settings. This problem is evermore important in a
highly technical field like radiation oncology and has translated to patient dissatisfaction
as physician retention rates in rural areas have decreased. 46 Traditional policymakers
have theorized that market forces and rural incentives would decrease geographic
disparities as the workforce increases. 49 However, we found little or no decrease in
geographic variability of radiation oncologists to accompany a growth in the workforce.
The significant non-physician personnel needed to operate radiation therapy facilities
could also be a factor in the geographic maldistribution of radiation oncologists. The
workforce shortages of radiation oncologists exacerbated with corresponding workforce
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shortages in non-physician personnel, such as dosimetrists and medical physicists 50,
perhaps make it difficult provide cost-effective quality radiation therapy in rural areas in
the United States. Recently, studies have suggested the solution to geographic
maldistribution is not increased recruitment to rural areas, but rather, technical
innovations that increase the efficiency of healthcare for rural populations. 51-54 An
example of a treatment innovation, specifically in radiation therapy, is hypofractionated
treatment, as performed for breast radiotherapy in Canada (the so-called, “Canadian
fractionation”) where geographic distance between radiation oncology centers is even
more severe than the United States.
We explored the implications of a geographically maldistributed workforce on
management of prostate cancer. Patients in HSAs without radiation oncologists were
more likely to choose active surveillance even when possessing high-risk disease.
Additionally, patients in HSAs lacking the presence of radiation oncologists were more
likely to undergo radical prostatectomy as primary treatment. Our findings corroborate
previous evidence that found an association with patient visits to urologists and radiation
oncologists and patient prostate cancer treatment choice.31,55 Our study highlights the
need for multidisciplinary care in order for patients to make informed decisions regarding
prostate cancer treatment. Additionally, recent evidence that suggests multidisciplinary
care alters treatment patterns for patients with localized prostate cancer.55 Interestingly,
we found primary care physician density to be associated with increased active
surveillance of prostate cancer. This is perhaps because patients who have access to
primary care physicians are more likely to successfully monitor low-risk prostate cancer
through active surveillance. Lastly, we confirmed previous evidence suggesting marital
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status, age, and patient race are related to patient decisions to pursue active surveillance
of prostate cancer in lieu of curative therapy.
The geographic distribution of the radiation oncology workforce is associated
with differences in prostate cancer mortality. The presence of a single radiation
oncologist in a county was associated with a statistically significant reduction in prostate
cancer specific mortality. The improvement in prostate cancer mortality persisted even
when adjusting for regional prostate cancer incidence, other physician densities, and
socioeconomic factors. Interestingly, incremental increases of radiation oncologists in a
county did not yield incremental benefits in outcomes, suggesting a ‘plateau effect’ when
a region becomes saturated with radiation oncologists. These results corroborate with
similar studies that found diminishing returns with increases in physician supply.15,56
Radiation therapy is one of the most common treatments for prostate cancer.
Although our study does not directly test the clinical implications of radiation therapy
and prostate treatment, it does highlight a potential association between the availability of
radiation therapy and improved prostate cancer outcomes. Radiation oncologist density
may be a surrogate for specialized oncology care, specifically the presence of large
cancer centers with multidisciplinary tumor boards and a variety of non-radiation prostate
cancer specialists. Although improved outcomes cannot definitively be attributed to the
presence of a radiation oncologist, our findings of improved prostate cancer mortality,
despite adjustment for urologist and allergist/immunologist density, speak to the
robustness of the specific association between radiation oncologist density and prostate
cancer mortality. Another possible explanation for our findings is that radiation
oncologists are a proxy for other general oncology indicators that could not be fully
	
  

39	
  

adjusted for in our multivariate model. For example, the presence of a large cancer center
with access to more advanced treatment technologies and multidisciplinary tumor boards
to better coordinate prostate cancer care between urologists and radiation oncologists.
Our study also highlighted previously cited racial disparities in prostate cancer outcomes.
Counties with larger proportions of Caucasians were associated with increased prostate
cancer mortality reduction. This is likely because minorities have been shown to present
with more advanced prostate cancer which carries a worse prognosis.57 Furthermore,
when adjusting for other factors known to influence cancer outcomes, such as
socioeconomic factors (median household income, population education level) the
presence of radiation oncologists was associated with prostate cancer mortality,
highlighting the relative uniqueness of radiation oncologist to prostate cancer
management.
Our, analysis found increasing urologist density to have a more profound effect
on prostate cancer specific mortality compared to radiation oncologist density. The
reasons for this are likely multifactorial. Firstly, because of greater number of urologists
compared to radiation oncologists the impact of urologists on prostate cancer mortality
maybe more easily seen. Secondly, because urologists are involved in the screening and
diagnosis of prostate cancer in addition to surgical treatment, increased density of
urologists may be associated with increased likelihood to be diagnosed at an earlier stage
with a more favorable prognosis. Conversely, radiation oncologists serve only a curative
role in prostate cancer treatment and require another clinical provider, typically a
urologists or primary care physician, to refer a prostate cancer patient to them. In a
counties with poor primary care and urologist presence radiation oncologists may be
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faced the challenge of treating higher stage prostate cancers that were not screened and
thusly diagnosed later.
County-level analysis confirmed the previously described geographic
maldistribution of radiation oncologists across health services areas. Large segments of
the population live in counties without a radiation oncologist, and this in turn is
associated with increased prostate cancer mortality. To complicate the problem, creating
an equitable distribution of radiation oncology services remains difficult. Unlike many
other medical specialties, radiation oncologists require significant equipment to provide
treatment, making radiation therapy relatively insular to increasingly popular
telemedicine initiatives. Additionally, the large investment required to start a radiation
oncology practice may contribute to apprehension of radiation oncologists entering the
field to establish a practice in an underserved area.
The mechanism by which radiation oncologist density is related to prostate cancer
mortality is difficult to pinpoint. Prior work has shown that radiation oncologist and
urologist density was not predictive of whether patients receive any curative therapy.
Rather, individual patient characteristics, such as marital status, are predictive of receipt
curative treatment.58 However, our previous analysis suggests radiation oncologist and
urologist density are predictive of whether patients choose radiation therapy or surgery as
the treatment modality for prostate cancer.59 It is plausible that regional physician density
is related to aspects of management about which patients are less informed, such as
nuanced treatment modalities, but decisions related to larger questions of whether to
receive curative treatment are ultimately personal ones. Furthermore, as geographic
differences in prostate cancer mortality have mainly been attributed to differences in
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disease stage related to time of diagnosis, an aspect of care with which radiation
oncologists are not typically involved, the density of radiation oncologists may be of less
utility.26 Perhaps it is the radiation oncologist’s role in providing truly multidisciplinary
cancer care that most influences mortality. Where previous investigators found an
association between urologist density and prostate cancer mortality, we found a similar
association for radiation oncologists, even when adjusting for the presence of urologists
and variations in prostate cancer incidence.15 Therefore, our two studies in combination
highlight the importance of multidisciplinary care in the management of patients with
prostate cancer.
We found that the improvement in prostate cancer mortality did plateau beyond a
radiation oncologist density of 1.0 per 100,000. Reasons for this diminishing return may
be because incremental improvement in prostate cancer mortality when comparing higher
density categories was small relative to the large improvement in mortality from the
addition of the first radiation oncologist to a county. This plateau effect has been seen in
similar studies of the physician, dermatology, neonatology workforces.5,8,56 Moreover,
prostate cancer can be relatively indolent, in contrast to cervical cancer or head and neck
cancers. Patients residing in areas with an oversubscribed radiation oncologist can
potentially wait until prostate cancer treatment is available, perhaps mitigating the need
for additional radiation oncologists to improve time between diagnosis and treatment.
Limitations
Our analysis has several limitations. First, the physician location data from the
AMA masterfile does not capture physicians who have multiple practices in different
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regions, and therefore it is possible that we have overestimated the geographic clustering
of radiation oncologists. However, though we believe that radiation oncologists are more
likely to have multiple physician practice locations compared to primary care providers,
we suspect that if radiation oncologists have multiple practices that they would be within
the same HSA. Unfortunately, this is unable to be confirmed by our data. Second, the
masterfile has been shown to underestimate physician shortages in rural areas. 60 Third,
our study does not capture other barriers to care such as lack of health insurance and
whether radiation oncology centers accept Medicaid payment for their services. Finally,
our analysis cannot provide an optimal ROR because we did not relate geographic
distribution to clinical outcomes. Future analysis should focus on finding the radiation
oncologist distribution that will optimize cancer outcomes. We were unable to assess the
impact of the availability of various radiation treatment modalities (EBRT, brachytherapy,
SBRT), as no information was recorded as to the type of treatment available at each
practice location. Another limitation of our study is the exclusion of rural counties when
studying the association between radiation oncologist density and mortality within the
United States. Unfortunately, the prostate cancer mortality data for some rural regions
was unavailable. Nevertheless even if that data were available, the paucity and relatively
maldistribution of radiation oncologists and urologists among rural counties would make
it difficult to establish any reliable relationship between physician density and prostate
cancer outcomes. What remains clear however is the variation in prostate cancer
outcomes in resource poor and resource rich regions. Further studies focused on rural
counties will be needed to better generalize the results of our analysis to rural areas.
Additionally, patient-specific characteristics were unattainable using the merged State
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Cancer Profiles data. Additionally, our analysis is subject to a theoretical lead-time bias
associated with patients in underserved areas potentially being diagnosed later and with
more advanced disease. This is due to a lack of available county-level stage and grade
data. This limitation is present in studies of this nature6,8 and was somewhat mitigated by
adjusting for geographic variations in prostate cancer incidence. Finally, given the
relative slow growth of prostate cancer, current mortality is likely related to treatment
options available upwards of 10-year prior. A multivariate model replacing current
physician densities with physician densities from 1995 yielded similar results. This is
likely because the geographic maldistribution of the radiation oncology and urology
workforces have remained relatively unchanged within the last 15 years.15,16 The
relationship between historical health system resources and long-term outcomes of a
population in the years following is an interesting topic for future studies. Nevertheless,
previously published studies of our similar nature6 our study is fundamentally an analysis
of the current variations in healthcare systems across the United States. Using current
physician densities as a proxy for current general oncology infrastructure and allows the
study the relative robustness of current healthcare systems. Our analysis ultimately
comments less on the well-established curative relationship between urologists and
radiation oncologists for prostate cancer, rather more on the relationship between
resource rich/poor regional healthcare systems and overall prostate cancer outcomes. In
spite of these limitations, our analysis provides a first step in understanding the
relationship between variations in the radiation oncologist workforce and prostate cancer
mortality and serves as an impetus for further study of the effect of regional radiation
oncologist therapy resources in the management of prostate cancer.
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Conclusion
In this comprehensive geographic analysis of the physician workforce we
highlighted a maldistribution of the radiation oncology workforce that has persisted for
over a decade. The geographic variations are associated with tangible differences in the
treatment of prostate cancer patients and regional prostate cancer mortality rates. Further
policy discussions addressing the physician workforce must focus not only on gross
numbers, but also geographic distribution. Although it is difficult to quantify the ideal
number of radiation oncologists needed in various regions in the United States, our study
raises questions regarding whether certain regions are lacking adequate numbers of
radiation oncologists. Geographic aware policies are needed to optimize the physician
workforce and provide quality oncology care throughout the United States.
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